Targeted Therapy for HER-Positive Breast Cancer

  • All patients with HER-2 positive breast cancer patients:
    • Who require systemic therapy should complete one year of HER2-targeted therapy:
      • Including those who achieve pathologic complete response after neoadjuvant chemotherapy
    • One could also consider continuing adjuvant pertuzumab in addition to trastuzumab:
      • Based on results from the phase III Aphinity trial:
        • Although patients who received neoadjuvant chemotherapy were not included in this trial
    • For patients who have residual disease and do not achieve complete pathologic response at the time of surgery:
      • Completion of one year of T-DM1 decreased the risk of recurrence of invasive breast cancer or death by 50% than with trastuzumab alone:
        • Based on results from KATHERINE trial:
          • The estimated percentage of patients who were free of invasive disease at 3 years was:
            • 88.3% in the T-DM1 group and 77.0% in the trastuzumab group
  • References:
    • von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer N Engl J Med. 2017;377(2):122-131.
    • von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-628.

#Arrangoiz #CancerSurgeon #BreastSurgeon #BreastCancer #CASO #CenterforAdvancedSurgicalOncology

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s